Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Rik Ossenkoppele, Ruben Smith, Niklas Mattsson, et al.
JAMA Neurology (2021) Vol. 78, Iss. 8, pp. 961-961
Open Access | Times Cited: 218

Showing 1-25 of 218 citing articles:

Biomarkers for neurodegenerative diseases
Oskar Hansson
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 954-963
Open Access | Times Cited: 717
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 426
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Rik Ossenkoppele, Rik van der Kant, Oskar Hansson
The Lancet Neurology (2022) Vol. 21, Iss. 8, pp. 726-734
Open Access | Times Cited: 276
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2381-2387
Open Access | Times Cited: 250
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, et al.
Nature Aging (2023) Vol. 3, Iss. 5, pp. 506-519
Open Access | Times Cited: 211
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
Bruna Bellaver, Guilherme Povala, Pâmela C.L. Ferreira, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1775-1781
Open Access | Times Cited: 163
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
Niklas Mattsson, Gemma Salvadó, Nicholas J. Ashton, et al.
JAMA Neurology (2023) Vol. 80, Iss. 4, pp. 360-360
Open Access | Times Cited: 156
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
Sergey Shcherbinin, Cynthia Evans, Ming‐Chi Lu, et al.
JAMA Neurology (2022) Vol. 79, Iss. 10, pp. 1015-1015
Open Access | Times Cited: 113
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Hugh Pemberton, Lyduine E. Collij, Fiona Heeman, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 10, pp. 3508-3528
Open Access | Times Cited: 106
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Daniel W. Sirkis, Luke W. Bonham, Taylor P. Johnson, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 6, pp. 2674-2688
Open Access | Times Cited: 88
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Alexa Pichet Binette, Nicolai Franzmeier, Nicola Spotorno, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 84
Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers
Todd E. Golde
Neurotherapeutics (2022) Vol. 19, Iss. 1, pp. 209-227
Open Access | Times Cited: 82
Detection and treatment of Alzheimer’s disease in its preclinical stage
Michael S. Rafii, Paul Aisen
Nature Aging (2023) Vol. 3, Iss. 5, pp. 520-531
Closed Access | Times Cited: 59
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 51
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Leonidas Chouliaras, John T. O’Brien
Molecular Psychiatry (2023) Vol. 28, Iss. 10, pp. 4084-4097
Open Access | Times Cited: 50
Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease
Tracy L. Young‐Pearse, Hyo Lee, Yi‐Chen Hsieh, et al.
Trends in Neurosciences (2023) Vol. 46, Iss. 6, pp. 426-444
Open Access | Times Cited: 47
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, et al.
Nature Aging (2024) Vol. 4, Iss. 5, pp. 694-708
Open Access | Times Cited: 36
Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals
Clifford R. Jack, Heather J. Wiste, Alicia Algeciras‐Schimnich, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 3, pp. 2143-2154
Open Access | Times Cited: 16
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer’s disease
Karly Alex Cody, Rebecca E. Langhough, Matthew Zammit, et al.
Brain (2024) Vol. 147, Iss. 6, pp. 2144-2157
Closed Access | Times Cited: 15
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 6
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Recent update on the heterogeneity of the Alzheimer’s disease spectrum
K. A. Jellinger
Journal of Neural Transmission (2021) Vol. 129, Iss. 1, pp. 1-24
Closed Access | Times Cited: 85
Genuine high-order interactions in brain networks and neurodegeneration
Rubén Herzog, Fernando E. Rosas, Robert Whelan, et al.
Neurobiology of Disease (2022) Vol. 175, pp. 105918-105918
Open Access | Times Cited: 62
Tau PET Imaging in Neurodegenerative Disorders
Colin Groot, Sylvia Villeneuve, Ruben Smith, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. Supplement 1, pp. 20S-26S
Open Access | Times Cited: 59
Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading
Lukas Frontzkowski, Michael Ewers, Matthias Brendel, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 54
Page 1 - Next Page

Scroll to top